SODIUM CHLORIDE 23.4% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Chloride 23.4%, and when can generic versions of Sodium Chloride 23.4% launch?
Sodium Chloride 23.4% is a drug marketed by Fresenius Kabi Usa, Hospira, and Abraxis Pharm. and is included in five NDAs.
The generic ingredient in SODIUM CHLORIDE 23.4% is sodium chloride. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the sodium chloride profile page.
Summary for SODIUM CHLORIDE 23.4%
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 3 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | SODIUM CHLORIDE 23.4% at DailyMed |
Pharmacology for SODIUM CHLORIDE 23.4%
| Drug Class | Osmotic Laxative |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM CHLORIDE 23.4%
US Patents and Regulatory Information for SODIUM CHLORIDE 23.4%
SODIUM CHLORIDE 23.4% is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting SODIUM CHLORIDE 23.4%
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | SODIUM CHLORIDE 23.4% | sodium chloride | INJECTABLE;INJECTION | 212248-001 | Apr 28, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hospira | SODIUM CHLORIDE 23.4% | sodium chloride | SOLUTION;INTRAVENOUS | 018897-003 | Jun 18, 2020 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Fresenius Kabi Usa | SODIUM CHLORIDE 23.4% | sodium chloride | INJECTABLE;INJECTION | 217796-001 | Jul 11, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Fresenius Kabi Usa | SODIUM CHLORIDE 23.4% | sodium chloride | SOLUTION;INTRAVENOUS | 212070-003 | Feb 14, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abraxis Pharm | SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER | sodium chloride | INJECTABLE;INJECTION | 019329-001 | Apr 22, 1987 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
